Understanding how to improve CAR T cell treatments for large B cell lymphoma patients
Official title: Learning features of optimal CAR T cells for LBCL from patient data
Funded at Stanford University · NIH-11256827 · Data updated 2026-11-12
This study is looking at how well CAR T cell therapies work for people with large B cell lymphoma, aiming to find the best types of these treatments and understand why some patients might not respond as well, so we can improve outcomes for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 4R00CA293149-02 |
| Project ID | NIH-11256827 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with large B cell lymphoma who are considering or undergoing CAR T cell therapy.
✕Less likely to help
Patients with other types of cancers or those who do not have large B cell lymphoma may not benefit from this research.
What this research studies
This research investigates the effectiveness of CAR T cell therapies specifically for patients with large B cell lymphoma (LBCL). By analyzing patient data, the study aims to identify the most effective CAR T cell subsets and understand the mechanisms that lead to treatment resistance. The approach combines experimental techniques with computational analysis to uncover insights that could enhance the efficacy of these immunotherapies. Patients may have their individual responses to CAR T cell therapy evaluated, contributing to a broader understanding of treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies, improving treatment outcomes for patients with large B cell lymphoma.
How similar studies have gone: Previous research has shown promising results in enhancing CAR T cell therapies, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Good, Zinaida — Stanford University
- Study coordinator: Good, Zinaida
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.